| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | GPRC6A; G-protein coupled receptor family C group 6 member A; hGPRC6A; G-protein coupled receptor GPCR33; hGPCR33 |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human GPRC6A. AA range:471-520 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets GPRC6A and detects endogenous levels of GPRC6A protein.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunofluorescence (IF) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | GPRC6A |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human |
| Purification | Affinity Purification |
| Molecular Weight | ~104.8 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human GPRC6A. AA range:471-520 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 222545 |
| UniProt | Q5T6X5 (Human: Q5T6X5; Mouse: Q8K4Z6) |
Scientific Background
Members of family C of the G protein-coupled receptor (GPCR) superfamily, such as GPRC6A, are characterized by an evolutionarily conserved amino acid-sensing motif linked to an intramembranous 7-transmembrane loop region. Several members of GPCR family C, including GPRC6A, also have a long N-terminal domain (summary by Pi et al. 2005 [PubMed 16199532]).
Alternative Names
GPRC6A; G-protein coupled receptor family C group 6 member A; hGPRC6A; G-protein coupled receptor GPCR33; hGPCR33
Safety & Handling
| Target | GPRC6A |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human |
| Purification | Affinity Purification |
| Molecular Weight | ~104.8 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human GPRC6A. AA range:471-520 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 222545 |
| UniProt | Q5T6X5 (Human: Q5T6X5; Mouse: Q8K4Z6) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunofluorescence (IF) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Members of family C of the G protein-coupled receptor (GPCR) superfamily, such as GPRC6A, are characterized by an evolutionarily conserved amino acid-sensing motif linked to an intramembranous 7-transmembrane loop region. Several members of GPCR family C, including GPRC6A, also have a long N-terminal domain (summary by Pi et al. 2005 [PubMed 16199532]).
Alternative Names
GPRC6A; G-protein coupled receptor family C group 6 member A; hGPRC6A; G-protein coupled receptor GPCR33; hGPCR33
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
